PARIS, France, May 7, 2024, 10:00 PM CEST – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutic treatments that exploit the body’s natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases, informs its shareholders that its ordinary annual and extraordinary general meeting (the “General Meeting”) will be held on May 30, 2024 at 10 a.m. (Paris time) in the offices of Dechert (Paris) LLP, located at 22 rue Bayard in Paris (75008).
The meeting notice including the agenda, draft resolutions and terms of participation in the General Meeting was published in the BALO of April 24, 2024 (no. 2400962).